GT Biopharma, Inc. Annual Report: A Year of Clinical Progress and Financial Restructuring

GT Biopharma, Inc. (the "Company") closed its fiscal year on December 31, 2025, having made significant strides in advancing its lead immunotherapy candidate, GTB3650, for oncology. This pivotal year saw major clinical progress alongside substantial financial and operational changes, notably a material restatement of previous financial reports.

Business Overview

GT Biopharma's core mission is to develop innovative treatments. A key achievement for the year was the progression of GTB3650, the Company's lead candidate from its proprietary TriKE® platform – a novel immunotherapy approach for oncology. In late 2024, GT Biopharma initiated a Phase 1/2 study for GTB3650 in patients with relapsed/refractory acute myeloid leukemia (AML) by entering a clinical trial agreement. Initial data from the dose-escalation phase showed promising safety profiles, which paves the way for further enrollment and dose optimization. The Company also strengthened its intellectual property portfolio through ongoing patent license and sponsored research agreements, supporting its long-term therapeutic strategy.

Financial Performance

As a clinical-stage biopharmaceutical company, GT Biopharma generated no significant product revenue in fiscal year 2025. The Company reported a substantial net loss of approximately $35.0 million, an increase from $28.5 million in the previous year. This rise primarily stemmed from increased research and development (R&D) expenses, which totaled $22.0 million (up from $18.0 million) as the Company advanced GTB3650 through clinical trials. General and administrative (G&A) expenses remained high at $10.0 million.

Risk Factors

The most significant and immediate risk identified during the year involved "Restatement Adjustments" to previously reported financial statements for the second and third quarters of 2025, and for the year-to-date. These adjustments, primarily due to complex revenue recognition accounting for certain agreements and internal control deficiencies, increased reported net losses and reduced shareholder equity. This restatement raises concerns about the reliability of financial reporting and internal controls, potentially impacting investor confidence and future financing terms. As a "Smaller reporting company" and "Non-accelerated filer," the Company may dedicate fewer resources to robust internal control systems compared to larger entities, which exacerbates this risk.

Beyond the restatement, key risks include the inherent uncertainties of clinical development. These uncertainties encompass potential trial delays, unfavorable clinical data, or failure to achieve regulatory approval. The Company operates in a highly competitive oncology market, competing against larger pharmaceutical companies with greater resources. The continuous need for capital raises poses a significant risk of shareholder dilution and potential financing on unfavorable terms. Furthermore, the success of the TriKE® platform is critical; any intellectual property challenges could severely impact its long-term viability.

Management Discussion (MD&A Highlights)

In 2025, the Company primarily focused on advancing its lead candidate, GTB3650, through a Phase 1/2 study in AML, supported by promising initial safety data. A notable operational shift occurred in July 2024 when GT Biopharma transitioned to a fully remote model, aiming to optimize cost structures and access a broader talent pool. Financially, the Company reported no product revenue and a net loss of $35.0 million, driven by increased R&D expenses of $22.0 million. Liquidity remains a critical focus. Cash and equivalents of $8.5 million provide a limited runway, necessitating ongoing capital raises, including $12.0 million in gross proceeds from a May 2025 Securities Purchase Agreement. A significant highlight and challenge was the restatement of prior financial reports. This restatement, due to accounting complexities and internal control deficiencies, impacted reported net losses and shareholder equity. To strengthen governance and clinical strategy, the Company implemented leadership changes, including appointing a new Chief Medical Officer and noting the departure of the former CFO.

Financial Health

GT Biopharma's financial health reflects that of a development-stage biotech, heavily relying on external financing. As of December 31, 2025, the Company reported cash and cash equivalents of approximately $8.5 million, a decrease from $15.2 million at the end of 2024. This cash position is estimated to provide a runway of only two to three quarters based on current burn rates. To fund its operations and clinical programs, the Company actively raised capital throughout the year. In May 2025, it completed a Securities Purchase Agreement, issuing Series L 10% Convertible Preferred Stock and Common Warrants, which raised gross proceeds of approximately $12.0 million. This financing activity continued into early 2026, underscoring the ongoing need for capital to sustain its R&D efforts. The Company also carries approximately $5.0 million in convertible debt, which could lead to further dilution if converted.

Future Outlook

GT Biopharma's future success hinges on the effective advancement of GTB3650 through its clinical development phases. Key milestones for 2026 include completing the Phase 1/2 dose-escalation portion and initiating expansion cohorts, with initial efficacy data anticipated in late 2026. The Company will continue to explore strategic partnerships and non-dilutive funding opportunities to complement its ongoing equity financing efforts. Effectively managing its financial resources and restoring investor confidence after the restatement will be critical for the Company's sustained growth and pipeline development.

Competitive Position

The Company operates in a highly competitive oncology market, competing against larger pharmaceutical companies with greater resources. Despite this, the broader market trend towards targeted immunotherapies and precision oncology treatments remains favorable for GT Biopharma's TriKE® platform. This platform is positioned as a novel immunotherapy approach. The TriKE® platform's success is critical for the Company to differentiate itself and compete effectively in this landscape.

In summary, GT Biopharma presents a high-risk, high-reward investment opportunity, balancing promising early clinical data for GTB3650 with significant financial and operational challenges, including the recent restatement and ongoing capital needs.